News | Radiation Oncology | November 23, 2015

The US Oncology Network identifies RaySearch as a New Preferred Provider

RaySearch is a preferred provider of radiation therapy treatment planning systems

Raystation

RaySearch Laboratories AB (publ) announced today that The US Oncology Network, one of America’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care, has selected RayStation to be offered throughout The US Oncology Network as one of the available radiation therapy treatment planning systems.

The US Oncology Network is comprised of more than 350 sites of care and approximately 1,000 independent, community-based physicians who treat more than 800,000 patients annually. 90 sites are radiation oncology facilities and about 140 physicians specialize in radiation oncology. Many of the centers offer a complete array of treatments to give patients a continuity of care that is state-of-the-art, yet cost effective. Physicians throughout The Network collaborate and take part in programs to assure that they are optimizing treatment possibilities.

“We initiated an effort almost two years ago to assess treatment planning solutions being developed in the marketplace,” said Jeff Limmer, director of medical physics and quality, The US Oncology Network. “In this era of quickly emerging technologies, it is extremely important to continually assess projected capability, and then to plan, in both clinically and fiscally responsible ways, for the incorporation of tools and resources which provide high quality care for patients. RayStation will be key in helping us achieve our goals.”

Marc Mlyn, president and CEO of RaySearch’s U.S. sales organization, RaySearch Americas, Inc., said, “There was a great deal of time and effort spent analyzing RayStation as a product and RaySearch as a company to be sure that practices in The US Oncology Network could achieve a high level of efficiency through centralized planning and remote access, and just as importantly that we had the ability to provide them with advanced technologies for the future. This is about a collaboration to put great technology into the hands of the practitioners in this very large network. We look forward to a long and successful future with them.”

Johan Löf, president and CEO of RaySearch, added, “It is satisfying to see that we are making our way into not only stand-alone centers and University Hospitals, but also into strategic and coordinated networks of community-based practices. This is a strong indicator that we are providing the products and services necessary to solidify our position as one of the leading suppliers of treatment planning systems in the U.S. market.”

Radiation therapy departments in The US Oncology Network now have the opportunity to select RayStation® as their treatment planning system. The first purchase made was at the Texas Center for Proton Therapy in June of 2015, previously announced.

For more information: www.raysearchlabs.com

 

Related Content

RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init